Clear Street initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $49 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating
- Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics
- Akero Therapeutics price target raised to $75 from $72 at H.C. Wainwright
- Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley
- Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position